Literature DB >> 16280778

Cyanoacrylic glue: a minimally invasive nonsurgical first line approach for the treatment of some urinary fistulas.

Giovanni Muto1, Leonardo D'Urso, Emanuele Castelli, Andrea Formiconi, Franco Bardari.   

Abstract

PURPOSE: We evaluated the adaptability and the efficacy of a cyanoacrylic glue for the conservative treatment of urinary fistulas of different etiologies using an endoscopic, percutaneous or endovaginal approach.
MATERIALS AND METHODS: From May 1998 to July 2004, 13 patients with long lasting iatrogenic and/or inflammatory urinary fistulas were treated conservatively with endoscopic, percutaneous or endovaginal application of 1 to 3 cc of cyanoacrylic glue.
RESULTS: The complication rate in this cohort of 13 patients was low. Occlusion therapy failed in 2 genitourinary fistulas which were wider (diameter greater than 1 cm) and short. In the remaining 11 cases urinary fistulas were successfully sealed and at a median followup of 35 months no relapses were observed.
CONCLUSIONS: Cyanoacrylic glue is suitable for endoscopic, percutaneous and endovaginal use. This occlusion therapy represents a safe and minimally invasive approach that might be offered as a first line option for the treatment of urinary fistulas, especially narrow and long tract fistulas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280778     DOI: 10.1097/01.ju.0000181809.51544.20

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Current Status of Hemostatic Agents and Sealants in Urologic Surgical Practice.

Authors:  Sashi S Kommu; Robert McArthur; Amr M Emara; Utsav D Reddy; Christopher J Anderson; Neil J Barber; Raj A Persad; Christopher G Eden
Journal:  Rev Urol       Date:  2015

Review 2.  Cyanoacrylic tissue glues: Biochemical properties and their usage in urology.

Authors:  Sema Nur Ayyıldız; Ali Ayyıldız
Journal:  Turk J Urol       Date:  2017-03-01

Review 3.  State of the Art for Treatment of Vesicovaginal Fistula.

Authors:  Rachel A Moses; E Ann Gormley
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

Review 4.  Current techniques for vesicovaginal fistula repair: surgical pearls to optimize cure rate.

Authors:  Brian L Cohen; Angelo E Gousse
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

5.  Percutaneous Management of Persistent Urine Leak After Partial Nephrectomy: Sealing the Leak Site with Glue.

Authors:  Ritesh Goel; Brusabhanu Nayak; Prabhjot Singh; Shivanand Gamanagatti; Richa Yadav
Journal:  J Endourol Case Rep       Date:  2020-12-29

6.  Renal artery embolization in the treatment of urinary fistula after renal duplication: A case report and review of literature.

Authors:  Tao Yang; Jun Wen; Tan-Tan Xu; Wen-Jing Cui; Jian Xu
Journal:  World J Clin Cases       Date:  2021-05-06       Impact factor: 1.337

7.  NBCA-Lipiodol Mixture Embolization of Persistent Urine Leakage After Orthotopic Neobladder Formation: Techniques and Outcomes.

Authors:  Jang Hee Han; Hyeong Dong Yuk; Jin Woo Choi; Ja Hyeon Ku
Journal:  Front Surg       Date:  2022-04-27

8.  Minimally invasive treatment of urinary fistulas using N-butyl-2-cyanoacrylate: a valid first line option.

Authors:  Cesare Selli; Maurizio De Maria; Michele Manica; Filippo Maria Turri; Francesca Manassero
Journal:  BMC Urol       Date:  2013-10-24       Impact factor: 2.264

9.  Conservative management of a delayed neovesicocutaneous fistula.

Authors:  Koichi Kodama; Yasukazu Takase; Isamu Motoi
Journal:  Case Rep Urol       Date:  2014-06-29

10.  2-octyl cyanoacrylate versus reintervention for closure of urethrocutaneous fistulae after urethroplasty for hypospadias: a randomized controlled trial.

Authors:  Gabriela Ambriz-González; Pedro Aguirre-Ramirez; José Manuel García-de León; Francisco Javier León-Frutos; Sergio Adrián Montero-Cruz; Xóchitl Trujillo; Clotilde Fuentes-Orozco; Michel Dassaejv Macías-Amezcua; Andrea del Socorro Álvarez-Villaseñor; Ana Olivia Cortés-Flores; Mariana Chávez-Tostado; Alejandro González-Ojeda
Journal:  BMC Urol       Date:  2014-11-21       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.